NeOnc Technologies Holdings is trading at $3.10, down 5.06%, with biotech-sector weakness a possible contributor; no clear company-specific catalyst has been identified. - NeOnc’s November 2 announcement that it will present NEO100 and NEO212 data at a November 13 conference does not establish a reason for the decline. - Nasdaq-listed XBI was lower in morning trading; reports differ on the sector decline’s size. The broader market was rising, and the move appears more consistent with sector than broad-market pressure.